Actively Recruiting
A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy for Abdominal and Lung Tumors
Led by The Christie NHS Foundation Trust · Updated on 2025-09-05
60
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying whether highly focused and intense radiation can be safely delivered to tumors in the abdominal area or chest using a high-strength MRI-guided radiotherapy machine called an MR-Linac. This approach aims to improve treatment by limiting radiation exposure to surrounding organs while providing better imaging and real-time treatment adaptation compared to standard x-ray guided methods. The study is observational and intends to compare patient experiences and outcomes with those receiving standard treatments. The study involves using MRI-guided stereotactic ablative radiotherapy (SABR) for patients with small, localized tumors in the thorax or abdomen. This method offers superior imaging during treatment, real-time adjustments, and the possibility to collect additional research images without extra radiation. Participants will receive treatment following established guidelines for abdominal or central lung SABR. Researchers will assess if MRI guidance improves treatment delivery and patient outcomes compared to standard care. Participants will be monitored to see if over 85% complete their radiotherapy as planned within 30 months. The study will collect data on patient experiences, tumor and tissue changes during treatment, and follow-up information for at least one year. Safety is carefully monitored, especially regarding MRI compatibility. The total participation time varies, with follow-up assessments to evaluate treatment success and patient well-being after therapy.
CONDITIONS
Brief Title
A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have no MRI contra-indications
- Eligible for abdominal SABR following NHSE SABR Consortium Guidelines or central lung SABR following RTOG Guidelines
- Able to give informed consent
- Anticipated life expectancy greater than 6 months
- No more than 3 oligometastatic sites treated in total
- Performance status of 2 or less
- Willing to attend follow-up visits and have data collected for at least 1 year
You will not qualify if you...
- Any contraindications to MRI detected after safety screening
- Unable to tolerate MRI scans
- Severe or uncontrolled systemic diseases that make participation undesirable
- Significant clinical disorders or lab findings deemed unsuitable by investigators
- Known active hepatitis B, hepatitis C, or HIV infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 30 months
Participants who undergo routine care are observed with MRI-guided Stereotactic Ablative Radiotherapy (SABR) for abdominal or lung tumors. Imaging is acquired during treatment to evaluate tumor motion and adaptation without additional radiation exposure.
Multiple visits during radiotherapy treatment
Duration - At least 1 year
Participants are followed up to collect data on treatment outcomes and any late effects for at least 1 year after radiotherapy.
Follow-up visits for at least 1 year
Trial Site Locations
Total: 1 location
1
The Christie NHS Foundation Trust
Manchester, United Kingdom, United Kingdom, M204BX
Actively Recruiting
Research Team
C
Clare Griffin
C
Cynthia Eccles
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here